医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

POLARIS Deploys Clinical Genomic Tests on DNAnexus Platform

2016年01月12日 PM10:00
このエントリーをはてなブックマークに追加


 

MOUNTAIN VIEW, Calif.

DNAnexus Inc., the leader in cloud-based genome informatics and data management, today announced that POLARIS (Personalized OMIC Lattice for Advanced Research and Improving Stratification), is now using DNAnexus to enable a series of genomic tests. The production-scale clinical applications will be used by the Genome Institute of Singapore (GIS). POLARIS was established by A*STAR (Agency for Science, Technology and Research) in 2011 to pilot the application of clinical omics in the treatment and diagnosis of medical diseases in Singapore.

POLARIS will leverage the DNAnexus Platform to support testing for gastrointestinal (GI) and solid tumor cancers. This is part of a systematic effort to develop a nationwide framework for omics-based tests.

Using DNAnexus, POLARIS was able to deploy its proprietary tests with full versioning, auditing, and dissemination using advanced permissions and access protocols on the DNAnexus network.

POLARIS is one of the first clinical laboratories in Singapore to achieve CAP accreditation specifically for massively parallel sequencing. POLARIS is currently using the DNAnexus Platform to deliver clinical genomic tests:

  • POLARIS GI Cancer Test – This assay detects somatic mutations for five genes with high clinical utility in colorectal cancer and gastrointestinal stromal tumors. Delivery of a diagnostic report, including interpretation of results is delivered to the treating physician responsible for deciding on appropriate course of treatment.
  • POLARIS XPLORA Panel Test – This panel targets more than 700 genes, selected from comprehensive review of cancer literature and six publicly available cancer genome databases. XPLORA is intended for basic and clinical research use in biomarker screening, development of companion diagnostics and focused disease panel tests.

“Working with DNAnexus, we were able to deploy our validated clinical pipeline into the cloud at production scale,” said Patrick Tan, MD, PhD, Program Director, POLARIS and Sr. Group Leader, Genome Institute of Singapore. “We look forward to leveraging the DNAnexus Platform to offer our genomic tests to the Singapore population and to expand our test portfolio.”

“The DNAnexus global network provides customers with a secure place for genomic data and allows users like POLARIS to keep pace with the growth of the global genetic testing market,” said Richard Daly, CEO of DNAnexus. “We are pleased that POLARIS chose DNAnexus to deploy their CAP-accredited workflow on our Platform and we look forward to our collaboration as they embark upon additional clinical opportunities to improve patient treatment.”

DNAnexus CEO Richard Daly will discuss the POLARIS deployment in addition to other case studies at the J.P. Morgan Healthcare conference today in San Francisco.

Date: January 12, 2016

Time: 2:00 pm Pacific

Location: Westin St. Francis, Elizabethan Room D

Title: The Network is the Solution in Genomics

Description: DNAnexus CEO Richard Daly presents the convergence of genomics and cloud computing and how DNAnexus has acquired market leadership in this sector by building out a global network via its integrated genome informatics and data management platform.

About DNAnexus

DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomics. DNAnexus provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. For more information please visit: https://dnanexus.com and follow us at @DNAnexus.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160112005429/en/

CONTACT

Element Public Relations for DNAnexus
Tim Smith, 415-350-3019
tsmith@elementpr.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Murata Invests in MEMS Sensor Manufacturing in Finland
  • Evaluate Ltd: Small Drug Developers Continue to Hold All the Cards, While Young Device Makers Suffer from a Shrinking Pool of Buyers
  • ABLIC Inc. Launches the S-85M0A Series of Ultra-High Efficiency Step-Down Switching Regulators in the Industry’s Most Compact(*) Size
  • Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation
  • 和铂医药与科伦博泰就PD-L1抗体A167开展全球战略合作